Viridian Therapeutics

Name

Viridian Therapeutics

Legal name

Viridian Therapeutics, Inc.

Website

https://viridiantherapeutics.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Biopharmaceuticals (Rare Disease / Autoimmune Antibody Therapeutics)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

Keywords

• Autoimmune disease therapeutics
• Thyroid eye disease treatment
• Monoclonal antibody development
• Rare disease biologics
• IGF-1R antibody therapy

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Lumvoa (veligrotug) Product Sales: Viridian's first commercial product following FDA approval on June 26, 2026. Revenue from wholesale acquisition of Lumvoa for thyroid eye disease, priced at approximately $450,000 per five-infusion course for an average 75kg patient. The company is building commercial infrastructure to compete directly with Amgen's Tepezza in the TED market.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Viridian Therapeutics develops and commercializes monoclonal antibody therapeutics for autoimmune and rare diseases, with a primary focus on thyroid eye disease (TED). Its lead commercial product, Lumvoa (veligrotug-vvze), is an FDA-approved intravenous anti-IGF-1R antibody administered as five 30–40 minute infusions over 12 weeks. The company's pipeline includes a subcutaneous anti-IGF-1R antibody (elegrobart) for self-administration, anti-FcRn candidates (VRDN-006, VRDN-008) for autoimmune disease, and a preclinical anti-TSHR program for TED and Graves' disease.

Product overview

Viridian Therapeutics is a biotechnology company developing a portfolio of antibody therapeutics for autoimmune and rare diseases, primarily focused on thyroid eye disease (TED). The company has transitioned from a development-stage to a commercial entity following FDA approval of its lead product Lumvoa (veligrotug-vvze), an intravenous IGF-1R antagonist. The pipeline includes Elegrobart (VRDN-003), a subcutaneous IGF-1R antibody for TED with BLA submission expected Q1 2027, an anti-TSHR program for TED and Graves' disease, and an FcRn portfolio (VRDN-006 and VRDN-008) for autoimmune diseases. The company's core strategy leverages antibody discovery and engineering expertise to develop differentiated therapeutic candidates for validated targets.

Differentiator

Problem solved

Functional benefit

Brands

• Lumvoa: Brand name for veligrotug (veligrotug-vvze), an IV treatment for thyroid eye disease
• ViridianCares
• Veligrotug
• Elegrobart

Products and services

• Lumvoa (veligrotug-vvze) An FDA-approved intravenous anti-IGF-1R monoclonal antibody for treating thyroid eye disease (TED) in both active and chronic forms. Administered as five infusions over 12 weeks (30–40 minute infusion time). First approved TED treatment with labeling covering both disease stages, based on THRIVE and THRIVE-2 Phase 3 trials. Priced at approximately $450,000 per five-infusion course for an average 75kg patient.
• Elegrobart (VRDN-003) A subcutaneously delivered, half-life-extended monoclonal antibody targeting IGF-1R for thyroid eye disease. Designed for self-administration via subcutaneous autoinjector with dosing every four or eight weeks. If approved, would be the first subcutaneous autoinjector treatment for TED. BLA submission targeted Q1 2027.
• VRDN-006 An anti-neonatal Fc receptor (FcRn)-targeting Fc fragment designed for convenient, self-administered subcutaneous delivery. Non-human primate studies demonstrated specificity for blocking FcRn-IgG interactions with comparable potency to efgartigimod. Currently in Phase 1 study.
• VRDN-008 A novel, first-in-class FcRn inhibitor designed for subcutaneous self-administration. Aims to pair IgG suppression with extended half-life technology, potentially enabling deeper and more durable suppression than existing anti-FcRn therapies. IND submitted.
• Anti-TSHR program A preclinical program developing a half-life extended monoclonal antibody that inhibits TSHR, designed for subcutaneous delivery in an autoinjector. Being developed for potential treatment of thyroid eye disease (TED) and Graves' disease.
• ViridianCares patient support program A comprehensive patient support program launched alongside Lumvoa to assist patients with access, reimbursement, co-pay support, and navigation services for the thyroid eye disease treatment.

Quantifiable outcome

• 48% placebo-adjusted proptosis responder rate in THRIVE Phase 3 trial
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• WuXi BiologicscoreTechnology or Integration · 27 May 2026Non-exclusive commercial supply agreement for veligrotug with commercial supply to begin upon FDA approval. The 5-year pact includes binding volume commitments and volume-based pricing. While WuXi Biologics was originally targeted by the Biosecure Act, the final legislation did not name the company, reducing regulatory risk for this supply arrangement.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Amgen: Amgen markets Tepezza (teprotumumab), the incumbent anti-IGF-1R therapy for thyroid eye disease and Viridian's primary competitor. Tepezza generates ~$1.9-2B in annualized revenue, making Amgen the most directly comparable competitive threat to Viridian's Lumvoa franchise.
• argenx: argenx markets efgartigimod (Vyvgart), an FcRn inhibitor for autoimmune IgG-mediated diseases including myasthenia gravis. Viridian's VRDN-006 and VRDN-008 programs target the same FcRn pathway, making argenx a direct competitor in the broader autoimmune pipeline.
• Horizon Therapeutics: Horizon originally developed and commercialized Tepezza before being acquired by Amgen. While now part of Amgen, Horizon's rare disease commercial model and Tepezza launch playbook provide a directly relevant template for Viridian's rare autoimmune disease strategy.

Emerging players

• Immunovant: Immunovant is developing anti-FcRn therapies (batoclimab, IMVT-1402) for multiple autoimmune indications. Competes with Viridian's VRDN-006/008 FcRn portfolio in the same mechanism class, with overlapping target indications.
• Krystal Biotech: Krystal Biotech is a commercial-stage rare disease biotech that successfully transitioned from development-stage to commercial entity with a focused launch. Comparable size, stage, and rare disease commercial infrastructure make it a relevant operational peer.
• Kiniksa Pharmaceuticals: Kiniksa is a commercial-stage biotech focused on autoimmune and rare diseases. Multiple Viridian executives (CEO Steve Mahoney, COO Tom Beetham, CHRO Melissa Manno) previously held senior roles at Kiniksa, making it a directly relevant operational and strategic peer.
• Caballeta Bio: Cabaletta Bio is a clinical-stage biotechnology company developing cell therapies for autoimmune diseases. While focused on a different modality, it competes for autoimmune disease pipeline assets and has overlap with Viridian's broader autoimmune strategy.
• Prothena: Prothena is a clinical-stage biotech developing therapies for proteinopathies and autoimmune diseases. Viridian CMO Radhika Tripuraneni previously served as Prothena's Chief Development Officer, and the company represents a relevant peer in autoimmune pipeline development.

Broad incumbents

• Regeneron Pharmaceuticals: Regeneron is a major biotechnology company with leading franchises in ophthalmology (Eylea) and immunology (Dupixent via Sanofi partnership). The Eylea franchise and broader ophthalmology infrastructure make Regeneron a strategic adjacent comparator for TED market dynamics.
• Sanofi: Sanofi has a major immunology franchise (Dupixent via Regeneron partnership) and rare disease presence (Genzyme legacy, where multiple Viridian executives worked). As a broad incumbent in autoimmune disease therapeutics, Sanofi represents both competitive and partnership dynamics relevant to Viridian's positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ViridianThera
• LinkedInlinkedin.com/company/viridiantx

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds34 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viridian Therapeutics